期刊文献+

垂体生长激素腺瘤药物治疗进展 被引量:1

原文传递
导出
摘要 垂体生长激素(GH)腺瘤占所有垂体腺瘤的20%-30%,患者主要产生内分泌紊乱症状及肿瘤占位导致的压迫症状(头痛、视力下降等)。前者多由血浆GH和胰岛素样生长因子-1(IGF-1)升高导致肢端肥大症,引起全身软组织、骨和软骨过度增生,并使糖尿病、高血压及心脑血管疾病、恶性肿瘤(如结肠癌)的发生率增加,严重威胁患者生命。垂体GH腺瘤的治疗方法包括手术、药物及放射治疗;大部分垂体GH腺瘤首选手术,其治愈缓解率为54%-80%”’;放疗和药物治疗均为辅助治疗,药物治疗近年来发展较快,本文简要综述如下。
出处 《中华神经外科杂志》 CSCD 北大核心 2009年第4期381-383,共3页 Chinese Journal of Neurosurgery
  • 相关文献

参考文献28

  • 1任祖渊.垂体腺瘤诊断和治疗现状[J].中国神经肿瘤杂志,2006,4(1):1-4. 被引量:10
  • 2Maiza JC, Vezzosi D, Matta M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf), 2007. 67: 282-289.
  • 3Casarini AP, Pinto EM, Jallad RS, et al. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest, 2006, 29 : 826- 830.
  • 4Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev, 2006, 27: 485-534.
  • 5Melmed S. Medical progress : Acromegaly. N Engl J Med, 2006, 355 : 2558-2573.
  • 6Hubina E, Nanzer AM, Hanson MR, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endoerinol, 2006, 155 : 371-379.
  • 7Sathyapalan T, Lowry M, Turnbull LW, et al. Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging. Pituitary, 2007, 10 : 233-236.
  • 8Colao A, Pivonello R, Auriemma RS, et al. Beneficial effe-ct of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol, 2007, 157 : 579-587.
  • 9Su DH, Liao KM, Chen HW, et al. Long-term primary medical therapy with somatostatin analogs in acromegaly. J Formos Med Assoc, 2006, 105 : 664- 669.
  • 10Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf), 2006, 64: 342-351.

二级参考文献43

  • 1毛志钢,王海军,何东升,徐伟光,冯雷.影响垂体生长激素腺瘤经蝶手术疗效的因素分析[J].中国微侵袭神经外科杂志,2006,11(4):151-153. 被引量:7
  • 2Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab, 2002, 87: 3013-3018.
  • 3Ayuk J, Stewart SE, Stewart PM, et al. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab, 2002, 87: 4142-4146.
  • 4Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab, 1998, 83: 3034-3040.
  • 5Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol(Oxf), 2000, 53: 577-586.
  • 6Wasko R, Ruchala M, Sawicka J, et al. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. J Endocrinol Invest, 2000, 23 : 12-18.
  • 7Heijckmann CA, Menheere PP, Sels JP, et al. Clinical experience with Sandostatin LAR in patients with acromegaly. Net J Med, 2001,59 : 286-291.
  • 8Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-Ⅰ, and tumor size. J Clin Endocrinol Metab, 2002, 87: 4554-4563.
  • 9Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab, 2001, 86:2779 -2786.
  • 10Herder WW, Lamberts SW. Somatostatin and somatostatin analogues : diagnostic and therapeutic uses. Curr Opin Oncol, 2002,14 : 53-57.

共引文献17

同被引文献8

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部